Tags

Type your tag names separated by a space and hit enter

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
AIDS. 2012 Feb 20; 26(4):F1-12.AIDS

Abstract

BACKGROUND

In an effort to raise protective antiviral immunity, dendritic cell immunotherapy was evaluated in six adults infected with human immunodeficiency virus (HIV)-1 and stable under highly active antiretroviral therapy (HAART).

DESIGN AND METHODS

Autologous monocyte-derived dendritic cells electroporated with mRNA encoding Gag and a chimeric Tat-Rev-Nef protein were administered, whereas patients remained on HAART. Feasibility, safety, immunogenicity and antiviral responses were investigated.

RESULTS

Dendritic cell vaccine preparation and administration were successful in all patients and only mild adverse events were seen. There was a significant increase post-dendritic cell as compared to pre-dendritic cell vaccination in magnitude and breadth of HIV-1-specific interferon (IFN)-γ response, in particular to Gag, and in T-cell proliferation. Breadth of IFN-γ response and T-cell proliferation were both correlated with CD4(+) and CD8(+) polyfunctional T-cell responses. Importantly, dendritic cell vaccination induced or increased the capacity of autologous CD8(+) T cells to inhibit superinfection of CD4(+) T cells with the vaccine-related IIIB virus and some but not all other HIV-1 strains tested. This HIV-1-inhibitory activity, indicative of improved antiviral response, was correlated with magnitude and breadth of Gag-specific IFN-γ response.

CONCLUSIONS

Therapeutic immunization with dendritic cells was safe and successful in raising antiviral cellular immune responses, including effector CD8(+) T cells with virus inhibitory activity. The stimulation of those potent immunological and antiviral effects, which have been associated with control of HIV-1, underscores the potential of dendritic cell vaccination in the treatment of HIV-1. The incomplete nature of the response in some patients helped to identify potential targets for future improvement, that is increasing antigenic spectrum and enhancing T-cell response.

Authors+Show Affiliations

Department of Biomedical Sciences, Division of Microbiology, Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22156965

Citation

Van Gulck, Ellen, et al. "MRNA-based Dendritic Cell Vaccination Induces Potent Antiviral T-cell Responses in HIV-1-infected Patients." AIDS (London, England), vol. 26, no. 4, 2012, pp. F1-12.
Van Gulck E, Vlieghe E, Vekemans M, et al. MRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS. 2012;26(4):F1-12.
Van Gulck, E., Vlieghe, E., Vekemans, M., Van Tendeloo, V. F., Van De Velde, A., Smits, E., Anguille, S., Cools, N., Goossens, H., Mertens, L., De Haes, W., Wong, J., Florence, E., Vanham, G., & Berneman, Z. N. (2012). MRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS (London, England), 26(4), F1-12. https://doi.org/10.1097/QAD.0b013e32834f33e8
Van Gulck E, et al. MRNA-based Dendritic Cell Vaccination Induces Potent Antiviral T-cell Responses in HIV-1-infected Patients. AIDS. 2012 Feb 20;26(4):F1-12. PubMed PMID: 22156965.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AU - Van Gulck,Ellen, AU - Vlieghe,Erika, AU - Vekemans,Marc, AU - Van Tendeloo,Viggo F I, AU - Van De Velde,Ann, AU - Smits,Evelien, AU - Anguille,Sébastien, AU - Cools,Nathalie, AU - Goossens,Herman, AU - Mertens,Liesbet, AU - De Haes,Winni, AU - Wong,Johnsson, AU - Florence,Eric, AU - Vanham,Guido, AU - Berneman,Zwi N, PY - 2011/12/14/entrez PY - 2011/12/14/pubmed PY - 2012/5/23/medline SP - F1 EP - 12 JF - AIDS (London, England) JO - AIDS VL - 26 IS - 4 N2 - BACKGROUND: In an effort to raise protective antiviral immunity, dendritic cell immunotherapy was evaluated in six adults infected with human immunodeficiency virus (HIV)-1 and stable under highly active antiretroviral therapy (HAART). DESIGN AND METHODS: Autologous monocyte-derived dendritic cells electroporated with mRNA encoding Gag and a chimeric Tat-Rev-Nef protein were administered, whereas patients remained on HAART. Feasibility, safety, immunogenicity and antiviral responses were investigated. RESULTS: Dendritic cell vaccine preparation and administration were successful in all patients and only mild adverse events were seen. There was a significant increase post-dendritic cell as compared to pre-dendritic cell vaccination in magnitude and breadth of HIV-1-specific interferon (IFN)-γ response, in particular to Gag, and in T-cell proliferation. Breadth of IFN-γ response and T-cell proliferation were both correlated with CD4(+) and CD8(+) polyfunctional T-cell responses. Importantly, dendritic cell vaccination induced or increased the capacity of autologous CD8(+) T cells to inhibit superinfection of CD4(+) T cells with the vaccine-related IIIB virus and some but not all other HIV-1 strains tested. This HIV-1-inhibitory activity, indicative of improved antiviral response, was correlated with magnitude and breadth of Gag-specific IFN-γ response. CONCLUSIONS: Therapeutic immunization with dendritic cells was safe and successful in raising antiviral cellular immune responses, including effector CD8(+) T cells with virus inhibitory activity. The stimulation of those potent immunological and antiviral effects, which have been associated with control of HIV-1, underscores the potential of dendritic cell vaccination in the treatment of HIV-1. The incomplete nature of the response in some patients helped to identify potential targets for future improvement, that is increasing antigenic spectrum and enhancing T-cell response. SN - 1473-5571 UR - https://www.unboundmedicine.com/medline/citation/22156965/mRNA_based_dendritic_cell_vaccination_induces_potent_antiviral_T_cell_responses_in_HIV_1_infected_patients_ L2 - https://doi.org/10.1097/QAD.0b013e32834f33e8 DB - PRIME DP - Unbound Medicine ER -